Pamela Stephenson Sells 3,137 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Pamela Stephenson sold 3,137 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,217.46. Following the sale, the insider now owns 69,529 shares in the company, valued at $3,794,892.82. The trade was a 4.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Disc Medicine Stock Down 0.2 %

Shares of Disc Medicine stock traded down $0.11 on Thursday, hitting $54.35. The stock had a trading volume of 369,811 shares, compared to its average volume of 402,546. Disc Medicine, Inc. has a twelve month low of $25.60 and a twelve month high of $77.60. The business’s 50 day moving average is $59.46 and its two-hundred day moving average is $55.02. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -13.66 and a beta of 0.73.

Hedge Funds Weigh In On Disc Medicine

Institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in Disc Medicine during the fourth quarter worth approximately $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Disc Medicine by 399.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,103 shares of the company’s stock worth $5,903,000 after purchasing an additional 74,454 shares during the last quarter. Woodline Partners LP lifted its stake in Disc Medicine by 5.2% during the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company’s stock worth $25,144,000 after purchasing an additional 19,538 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Disc Medicine by 26.5% in the 4th quarter. ProShare Advisors LLC now owns 6,966 shares of the company’s stock valued at $442,000 after acquiring an additional 1,458 shares during the last quarter. Finally, MPM Bioimpact LLC lifted its stake in shares of Disc Medicine by 11.1% in the 4th quarter. MPM Bioimpact LLC now owns 346,401 shares of the company’s stock valued at $21,962,000 after acquiring an additional 34,640 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analysts Set New Price Targets

IRON has been the topic of several analyst reports. Stifel Nicolaus upped their target price on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Wedbush reiterated an “outperform” rating and set a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, Jefferies Financial Group initiated coverage on Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target on the stock. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $88.90.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.